147 related articles for article (PubMed ID: 30771285)
41. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
42. Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
Kang HW; Seo SP; Byun YJ; Piao XM; Kim YH; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2018 Aug; 16(4):274-280. PubMed ID: 29571585
[TBL] [Abstract][Full Text] [Related]
43. Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.
Mengual L; Frantzi M; Mokou M; Ingelmo-Torres M; Vlaming M; Merseburger AS; Roesch MC; Culig Z; Alcaraz A; Vlahou A; Mischak H; Van der Heijden AG
Br J Cancer; 2022 Nov; 127(11):2043-2051. PubMed ID: 36192490
[TBL] [Abstract][Full Text] [Related]
44. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
[TBL] [Abstract][Full Text] [Related]
45. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
46. Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review.
Agreda Castañeda F; Raventós Busquets CX; Morote Robles J
Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):404-413. PubMed ID: 31097210
[TBL] [Abstract][Full Text] [Related]
47. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
48. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
49. MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection.
Pospisilova S; Pazourkova E; Horinek A; Brisuda A; Svobodova I; Soukup V; Hrbacek J; Capoun O; Hanus T; Mares J; Korabecna M; Babjuk M
Neoplasma; 2016; 63(5):799-808. PubMed ID: 27468885
[TBL] [Abstract][Full Text] [Related]
50. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer.
Mengual L; Lozano JJ; Ingelmo-Torres M; Gazquez C; Ribal MJ; Alcaraz A
Int J Cancer; 2013 Dec; 133(11):2631-41. PubMed ID: 23686449
[TBL] [Abstract][Full Text] [Related]
51. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
52. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
53. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
[TBL] [Abstract][Full Text] [Related]
54. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
[TBL] [Abstract][Full Text] [Related]
55. Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study.
Fasulo V; Paciotti M; Lazzeri M; Contieri R; Casale P; Saita A; Lughezzani G; Diana P; Frego N; Avolio PP; Colombo P; Elefante GM; Guazzoni G; Buffi NM; Bates M; Hurle R
Front Oncol; 2022; 12():832835. PubMed ID: 35155263
[TBL] [Abstract][Full Text] [Related]
56. Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer.
Ingelmo-Torres M; Lozano JJ; Izquierdo L; Carrion A; Costa M; Gómez L; Ribal MJ; Alcaraz A; Mengual L
Oncotarget; 2017 Mar; 8(11):18238-18247. PubMed ID: 28212556
[TBL] [Abstract][Full Text] [Related]
57. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
Yossepowitch O; Herr HW; Donat SM
J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the diagnostic accuracy of UBC
Styrke J; Henriksson H; Ljungberg B; Hasan M; Silfverberg I; Einarsson R; Malmström PU; Sherif A
Scand J Urol; 2017 Aug; 51(4):293-300. PubMed ID: 28422550
[TBL] [Abstract][Full Text] [Related]
59. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
60. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
Kawakami K; Enokida H; Tachiwada T; Gotanda T; Tsuneyoshi K; Kubo H; Nishiyama K; Takiguchi M; Nakagawa M; Seki N
Oncol Rep; 2006 Sep; 16(3):521-31. PubMed ID: 16865252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
